Axsome Q2 product revenue $46.7M; Auvelity sales $27.6M, up 76% sequentially

Axsome Therapeutics, Inc.

2023-Q2 EPS reported -$1.80 revenue$31,300,000

Total product revenue $46.7M vs $8.8M in Q2 2022 (Auvelity $27.6M, Sunosi $19.1M).
Net loss $67.2M ($1.54/share) vs $41.4M loss in prior year; cash $437.1M at June 30, 2023.
Expanding Auvelity sales force from 162 to 260 reps to reach 44,000 physicians.
Initiated FOCUS Phase 3 trial of solriamfetol in ADHD; plans Phase 3 trials in binge eating (Q4 2023) and shift work disorder (Q1 2024).
Anticipates AXS-12 narcolepsy Phase 3 topline in Q4 2023 and AXS-05 Alzheimer's agitation data in H1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Axsome Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: revenue $46.7 million, net income $(1.54) per share.

Period: the second quarter ended June 30, 2023
Revenue: $46.7 million
Net income: $(1.54) per share
Result: reported results

Exact text from the filing

--- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Axsome Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update Total 2Q 2023 product revenue of $46.7 million Auvelity ® 2Q 2023 net product sales of $27.6 million, representing 76% quarter-over-quarter growth Sunosi ® 2Q 2023 net product revenue of $19.1 million Pro forma second quarter

View on SEC.gov

Browse all earnings releases →

Axsome Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-039035

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.